DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Completed

Conditions: Localized Non-Resectable Adult Liver Carcinoma

Interventions: Other: Yttrium-90 Resin Microspheres

First Posted Date: 2016-02-19

Last Posted Date: 2021-09-05

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 1653

Registration Number: NCT02685631

Locations: 🇺🇸
Sky Ridge Medical Center, Englewood, Colorado, United States
🇺🇸
Methodist Health System, Dallas, Texas, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 39 locations

Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis

Not Applicable

Completed

Conditions: Pleural Effusion

Interventions: Other: Manometry-guided thoracentesis
Other: Symptom-guided thoracentesis

First Posted Date: 2016-02-09

Last Posted Date: 2019-09-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 89

Registration Number: NCT02677883

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis

Completed

Conditions: Lymphedema

Interventions: Procedure: Medical Examination
Other: Questionnaire Administration
Procedure: Shear Wave Elastography

First Posted Date: 2016-02-08

Last Posted Date: 2022-02-09

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 80

Registration Number: NCT02676752

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Progesterone Receptor Negative
Triple-Negative Breast Carcinoma
HER2/Neu Negative
Estrogen Receptor Negative
Stage IV Breast Cancer
Recurrent Breast Carcinoma

Interventions: Drug: Galunisertib
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2016-02-03

Last Posted Date: 2023-11-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 29

Registration Number: NCT02672475

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia With Multilineage Dysplasia
Myeloid Sarcoma
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
Therapy-Related Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Vosaroxin

First Posted Date: 2016-01-18

Last Posted Date: 2025-04-15

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 42

Registration Number: NCT02658487

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Phase 1

Completed

Conditions: Myelofibrosis
Polycythemia Vera

Interventions: Drug: TGR-1202
Drug: ruxolitinib

First Posted Date: 2015-07-09

Last Posted Date: 2024-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 60

Registration Number: NCT02493530

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Mays Cancer Center at University of Texas Health San Antonio, San Antonio, Texas, United States
🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States

and more 2 locations

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Phase 3

Completed

Conditions: Malignant Head and Neck Neoplasm
Mucositis
Radiation-Induced Disorder

Interventions: Other: Educational Intervention
Other: Pain Therapy
Drug: Gabapentin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Oxycodone/Acetaminophen
Drug: Hydrocodone/Acetaminophen
Drug: Fentanyl
Drug: Ibuprofen
Drug: Magic Mouthwash

First Posted Date: 2015-06-24

Last Posted Date: 2021-02-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 79

Registration Number: NCT02480114

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Estrogen Receptor Positive
Stage IV Breast Cancer
Estrogen Receptor Negative
Progesterone Receptor Negative
Progesterone Receptor Positive
HER2/Neu Negative
Triple-Negative Breast Carcinoma

Interventions: Other: Biomarker Analysis
Drug: Enzalutamide
Other: Pharmacological Study
Drug: Taselisib

First Posted Date: 2015-05-29

Last Posted Date: 2022-08-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT02457910

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 9 locations

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

Phase 2

Completed

Conditions: Lung Carcinoma
Solitary Pulmonary Nodule
Cigarette Smoking Behavior

Interventions: Procedure: Computed Tomography
Radiation: fluorodeoxyglucose F-18
Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography
Procedure: Positron Emission Tomography (PET)

First Posted Date: 2015-05-19

Last Posted Date: 2022-10-19

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 46

Registration Number: NCT02448225

Locations: 🇺🇸
Tennessee Valley Health System Nashville, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers

Not Applicable

Terminated

Conditions: Cancer

Interventions: Other: Educational Intervention
Other: Follow-Up Care
Procedure: Psychosocial Assessment and Care
Other: Questionnaire Administration

First Posted Date: 2015-05-12

Last Posted Date: 2019-10-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 67

Registration Number: NCT02440737

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Meharry Medical College, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy